Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis

Hepatology

Volumn 36, Issue 5, 2002, Pages 1070-1078

  Moreau, Richard ^a   Barrière, Eric ^a   Tazi, Khalid A ^a   Lardeux, Bernard ^b   Dargère, Delphine ^c   Urbanowicz, Waldemar ^a   Poirel, Odile ^a   Chauvelot Moachon, Laurence ^c   Guimont, Marie Christine ^a   Bernuau, Dominique ^b   Lebrec, Didier ^a  

^a BEAUJON HOSPITAL   (France)

^b INSERM   (France)

^c NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; TERLIPRESSIN;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BILIARY CIRRHOSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; HEMODYNAMIC MONITORING; HYPOTENSION; IN VIVO STUDY; INHIBITION KINETICS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SEPTIC SHOCK; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0036828764     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36501     Document Type: Article

References (39)

1. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993;18:353-358.
2. Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin Liver Dis 1997;17:203-216.
3. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995;81:641-650.
4. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
5. Xie QW, Nathan C. The high-output nitric oxide pathway: Role and regulation. J Leukoc Biol 1994;56:576-582.
6. Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Ann Rev Pharmacol Toxicol 1999;39:191-220.
7. Meyer J, Traber LD, Nelson S, Lentz CW, Nakazawa H, Herndon DN, Noda H, et al. Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J Appl Physiol 1992;73:324-328.
8. Stoclet JC, Fleming I, Gray G, Julou-Schaeffer G, Schneider F, Schott C, Schott C, et al. Nitric oxide and endotoxemia. Circulation 1993;87(Suppl V):V77-V80.
9. Szabo C, Southan G, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci U S A 1994;91:12472-12476.
10. Hoque AM, Papapetropoulos A, Venema RC, Catravas JD, Fuchs LC. Effects of antisense oligonucleotide to iNOS on hemodynamic and vascular changes induced by LPS. Am J Physiol 1998;275:H1078-H1083.
11. Beasley D, Cohen RA, Levinsky NG. Endotoxin inhibits contraction of vascular smooth muscle in vitro. Am J Physiol 1990;258:H1187-H1192.
12. Fox GA, Paterson NAM, McCormack DG. Effect of inhibition of NO synthase on vascular reactivity in a rat model of hyperdynamic sepsis. Am J Physiol 1994;267:H1377-H1382.
13. Hollenberg SM, Cunnion RE, Zimmerberg J. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats. Am J Physiol 1993;264:H660-H663.
14. Gunnett CA, Chu Y, Heistad DD, Loihl A, Faraci FM. Vascular effects of LPS in mice deficient in expression of the gene inducible nitric oxide synthase. Am J Physiol 1998;275:H416-H421.
15. Hollenberg SM, Broussard M, Osman J, Parrillo JE. Increased microvascular reactivity and improved mortality in septic mice lacking inducible nitric oxide synthase. Circ Res 2000;86:774-779.
16. Lefilliatre P, Sogni P, Bertrand V, Del Soldato P, Pateron D, Moreau R, Lebrec D. Aortic hyporeactivity to norepinephrine induced by lipopolysaccharide in cirrhotic rats: Beneficial effects of a non-steroidal anti-inflammatory drug coupled with a nitric oxide donor. J Gastroenterol Hepatol 2001;16:70-78.
17. Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-1282.
18. Landry DW, Levin HR, Gallant EM, Ashton RC, Seo S, D'Alessandro D, Oz MC, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-1125.
19. Yamamoto K, Ikeda U, Okada K, Saito T, Shimada K. Arginine vasopressin inhibits nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells. Hypertens Res 1997;20:209-216.
20. Umino T, Kusano E, Muto S, Akimoto T, Yanagiba S, Ono S, Amemiya M, et al. AVP inhibits LPS- and IL-1β-stimulated NO and cGMP through VI receptor in cultured rat mesangial cells. Am J Physiol 1999;276:F433-F441.
21. Lee SS, Girod C, Braillon A, Hadengue A, Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: Effects of pentobarbital sodium. Am J Physiol 1986;251:G176-G180.
22. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: A new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984;65:305-311.
23. Lebrec D, Moreau R, Cailmail S, Sogni P, Oberti F, Hadengue A. Effects of terlipressin on hemodynamics and oxygen content in conscious portal vein stenosed and cirrhotic rats receiving propranolol. J Hepatol 1993;17:102-107.
24. + ATPase activity and phosphorylation in aortae from rats with cirrhosis. Hepatology 1998;28:663-669.
25. + channels in in vitro NO-mediated aortic hyporeactivity to α-adrenergic vasoconstriction in rats with cirrhosis. J Hepatol 2001;35:350-357.
26. Zheng XL, Gui Y, Sharkey KA, Hollenberg MD. Differential induction of nitric oxide synthase in rat gastric and vascular smooth muscle tissue: Distinct tissue distribution and distinctive signaling pathways. J Pharmacol Exp Ther 1999;289:632-640.
27. Binion DG, Fu S, Ramanujam KTS, Chai YC, Dweik RA, Drazba JA, Wade JSG, et al. iNOS expression in human intestinal microvascular endothelial cells inhibits leucocyte adhesion. Am J Physiol 1998;275:G592-G603.
28. 6-(1-iminoethyl)lysine: A selective inhibitor of inducible nitric oxide synthase. J Med Chem 1994;37:3886-3888.
29. Pateron D, Tazi KA, Sogni P, Heller J, Chagneau C, Poirel O, Philippe M, et al. Role of nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. Gastroenterology 2000;119:196-200.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-354.
31. Yared A, Kon V, Ichikawa I. Mechanism of preservation of glomerular perfusion and filtration during acute extracellular fluid volume depletion. Importance of intrarenal vasopressin-prostaglandin interaction for protecting kidneys from constrictor action of vasopressin. J Clin Invest 1985;75:1477-1487.
32. Kaabache T, Barraud B, Feldmann G, Bernuau D, Lardeux B. Direct solution hybridization of guanidine thiocyanate-solubilized cells for quantitation of mRNAs in hepatocytes. Anal Biochem 1995;232:225-230.
33. Fort P, Marty L, Piechaczyk M, el Sabrouty S, Dani C, Jeanteur P, Blanchard JM. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 1985;13:1431-1442.
34. Heller J, Sogni P, Barrière E, Tazi KA, Chauvelot-Moachon L, Guimont MC, Bories PN, et al. Effects of lipopolysaccharide on TNF-α production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol 2000;33:376-381.
35. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998;12:1035-1044.
36. Schrier RW, Briner V, Caramelo C. Cellular action and interactions of arginine vasopressin in vascular smooth muscle: Mechanisms and clinical implications. J Am Soc Nephrol 1993;4:2-11.
37. Tazi KA, Barrière E, Moreau R, Heller J, Sogni P, Pateron D, Poirel O, et al. Role of shear stress in aortic eNOS up-regulation in rats biliary with cirrhosis. Gastroenterology 2002;122:1869-1877.
38. Hewett JA, Roth RA. Hepatic and extrahepatic pathobiology of bacterial lipopolysaccharides. Parmacol Rev 1993;45:381-411.
39. Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Assous M, Sicot C. Clinical, hemodynamic and metabolic characteristics and ICU outcome of septic shock in patients with cirrhosis. Crit Care Med 1992;20:746-750.